Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001019056-17-000595
Filing Date
2017-06-30
Accepted
2017-06-30 09:55:16
Documents
5
Group Members
DAVID HURWITZJOHN T. BIRDNEIL H. KOFFLERPETER M. COLLERYSC FUND MANAGEMENT PROFIT SHARING PLANSC FUNDAMENTAL LLCSC FUNDAMENTAL VALUE FUND, L.P.

Document Format Files

Seq Description Document Type Size
1 SC 13D aviragen_13d.htm SC 13D 214133
2 EXHIBIT1 ex_1.htm EX-1 18618
3 EXHIBIT 2 ex_2.htm EX-2 1781
4 GRAPHIC ex_2page001.jpg GRAPHIC 60803
5 GRAPHIC ex_2page002.jpg GRAPHIC 45659
  Complete submission text file 0001019056-17-000595.txt   383500
Mailing Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009
Business Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009 301-770-3099
Aviragen Therapeutics, Inc. (Subject) CIK: 0000072444 (see all company filings)

EIN.: 591212264 | State of Incorp.: DE | Fiscal Year End: 0630
Type: SC 13D | Act: 34 | File No.: 005-31596 | Film No.: 17940605
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O SC FUNDAMENTAL LLC 747 THIRD AVENUE, 27TH FLOOR NEW YORK NY 10017
Business Address C/O SC FUNDAMENTAL LLC 747 THIRD AVENUE, 27TH FLOOR NEW YORK NY 10017 212-888-9100
SC Fundamental Value Fund, L.P. (Filed by) CIK: 0001322318 (see all company filings)

EIN.: 133563962 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D